AZD8931, an inhibitor of EGFR, ERBB2 and ERBB3 signalling, in combination with FOLFIRI: A Phase I/II study to determine the importance of schedule and activity in colorectal cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Sapitinib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms PANTHER
- 08 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Oct 2016 Planned End Date changed from 1 May 2018 to 1 Dec 2020.
- 03 Oct 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Aug 2020.